2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
3
Conditions
Carcinoma, Non-Small-Cell Lung
10
Uterine Cervical Neoplasms
8
Squamous Cell Carcinoma of Head and Neck
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Carcinoma, Renal Cell
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Melanoma
3
Lung Neoplasms
3
Solid Tumor
2
Ovarian Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Kidney Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumors
1
Solid Tumor, Unspecified, Adult
1
Sarcoma
1
Interventions
Carboplatin
345
Cisplatin
240
Paclitaxel
208
Radiotherapy
206
Pemetrexed
190
Docetaxel
170
Gemcitabine
158
pembrolizumab
146
Erlotinib Hydrochloride
111
Magnetic Resonance Spectroscopy
101
Etoposide
98
Bevacizumab
96
Specimen Handling
84
Nivolumab
77
durvalumab
73
Radiosurgery
73
Blood Specimen Collection
65
Drug Therapy
61
osimertinib
56
Vinorelbine
54
Gefitinib
50
Surveys and Questionnaires
48
atezolizumab
44
Biopsy
43
Irinotecan
42
Radiation
41
Topotecan
39
Standard of Care
38
Cyclophosphamide
38
Surgical Procedures, Operative
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
zimberelimab
×
Clear all
NCT04736173
2026-05-01
ARC-10
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
169 enrolled
NCT05633667
2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2
Recruiting
270 enrolled
NCT04262856
2025-08-26
ARC-7
Arcus Biosciences, Inc.
Phase 2
Completed
151 enrolled